Oxcia AB (publ)

Oxcia AB (publ) is at the forefront of biotechnology research, pioneering breakthrough therapies that target DNA Damage Response (DDR) to combat cancer and inflammation. With a strong focus on innovative solutions, Oxcia AB is dedicated to advancing healthcare through cutting-edge research and development. The company's commitment to excellence drives its pursuit of novel therapeutic approaches. Oxcia AB's primary address is Norrbackagatan 70C, Stockholm, SE.

Leveraging its O2-DDR technology platform, Oxcia AB is developing a robust portfolio of projects, including OXC-101 for cancer and OXC-201 for pulmonary fibrosis. These advanced projects highlight Oxcia AB's capabilities in addressing critical medical needs. The company also explores opportunities in psoriasis and other undisclosed discovery projects, showcasing its broad research interests and potential for future breakthroughs.

Oxcia AB (publ) is committed to making a significant impact on global health through its dedication to pioneering therapies. Management is continuously working to complete further details about Oxcia AB, ensuring comprehensive information is available soon. We invite the manager of Oxcia AB (publ) to create a customized and exclusive company showcase and product listing on our platform to further enhance your company's visibility and commercial development.